Initial Canadian Experience of Prostate Artery Embolization for Symptomatic Benign Prostatic Hyperplasia: Midterm...

Area of Science:

• Interventional Urology
• Minimally Invasive Therapies
• Urologic Oncology

Background:

• Benign prostatic hyperplasia (BPH) is a common condition affecting aging men.
• Prostate artery embolization (PAE) is an emerging minimally invasive treatment option for BPH.
• Midterm outcomes and safety data for PAE in BPH are still being established.

Purpose of the Study:

• To evaluate the midterm outcomes and safety of PAE for BPH treatment.
• To assess changes in prostate volume, International Prostate Symptom Score (IPSS), quality of life (QoL), International Index for Erectile Function (IIEF-5), uroflowmetry, and adverse events post-PAE.

Main Methods:

• A retrospective review of 80 male patients who underwent PAE for BPH was conducted.
• Validated questionnaires (IPSS, QoL, IIEF-5) and uroflowmetry (Qmax, PVR) were used for assessment at baseline and 12 months.
• Prostate imaging was performed pre-procedure and at 3 and 12 months post-procedure.

Main Results:

• Prostate volume significantly decreased by 27.5% at 12 months post-PAE (P < .05).
• Significant improvements were observed in IPSS (21.8 to 10.5) and QoL (4.5 to 2.0) (P < .05).
• Uroflowmetry showed significant improvement in Qmax (5.9 to 10.0 mL/s) and reduction in PVR (202 to 105 mL) (P < .05), with no significant change in IIEF-5.

Conclusions:

• PAE offers a clinically and statistically significant reduction in prostate volume for BPH patients.
• PAE leads to substantial improvements in urinary symptoms, quality of life, and uroflowmetry parameters.
• The procedure demonstrated a favorable safety profile with no major complications reported.